Azelastine/budesonide intranasal - Sedor

Drug Profile

Azelastine/budesonide intranasal - Sedor

Alternative Names: Captisol-enabled™ Budesonide + Azelastine nasal spray - Sedor; CDX-313; LGD-313

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CyDex Pharmaceuticals
  • Developer Sedor Pharmaceuticals
  • Class Glucocorticoids; Phthalazines; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Histamine H1 receptor antagonists; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Seasonal allergic rhinitis

Most Recent Events

  • 04 Oct 2017 Azelastine/budesonide is still at phase II development stage for Seasonal allergic rhinitis in Canada (Intranasal) (Sedor Pharmaceuticals website, October 2017)
  • 08 Dec 2015 Captisol-enabled™ azelastine/budesonide licensed to RODES Pharmaceuticals in USA
  • 08 Dec 2015 RODES plans a phase I trial for Seasonal allergic rhinitis in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top